Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1977 1
1978 1
1979 1
1980 1
1981 1
1982 2
1983 1
1984 1
1985 5
1986 4
1987 4
1988 6
1989 5
1990 4
1991 7
1992 6
1993 10
1994 4
1995 3
1996 8
1997 5
1998 3
1999 4
2000 7
2001 6
2002 6
2003 9
2004 6
2005 5
2006 7
2007 15
2008 14
2009 12
2010 12
2011 9
2012 6
2013 3
2014 9
2015 10
2016 8
2017 14
2018 7
2019 3
2020 6
2021 4
2022 7
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Results by year

Filters applied: . Clear all
Page 1
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
At median follow-up of 30 months (IQR 22-38), patients treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-60), compared with 23% (14-31) of those treated with methotrexate-cytarabine alone (hazard ratio 0.46, 95% CI 0.28-0.74) and 30% (21-4 …
At median follow-up of 30 months (IQR 22-38), patients treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-6 …
Cytarabine-Induced Encephalitis.
Lenfant C, Greiner N, Duprez T. Lenfant C, et al. J Belg Soc Radiol. 2021 Sep 16;105(1):46. doi: 10.5334/jbsr.2492. eCollection 2021. J Belg Soc Radiol. 2021. PMID: 34611580 Free PMC article.
Teaching Point: Central nervous system adverse effects of cytarabine treatment include aseptic meningitis, myelopathy, and more rarely, encephalopathy, seizures, and cerebellar dysfunction. This case illustrates a cytarabine-induced encephalitis with predominant cer …
Teaching Point: Central nervous system adverse effects of cytarabine treatment include aseptic meningitis, myelopathy, and more rarel …
How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. Calimeri T, et al. ESMO Open. 2021 Aug;6(4):100213. doi: 10.1016/j.esmoop.2021.100213. Epub 2021 Jul 13. ESMO Open. 2021. PMID: 34271311 Free PMC article. Review.
In patients aged 70 years or younger, MATRix (HD-MTX/cytarabine/thiotepa/rituximab) chemotherapy followed by consolidative high-dose chemotherapy plus autologous stem cell transplantation or whole-brain irradiation has been associated with a significant improvement in over …
In patients aged 70 years or younger, MATRix (HD-MTX/cytarabine/thiotepa/rituximab) chemotherapy followed by consolidative high-dose …
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Morris PG, et al. J Clin Oncol. 2013 Nov 1;31(31):3971-9. doi: 10.1200/JCO.2013.50.4910. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101038 Free PMC article. Clinical Trial.
Consolidation cytarabine was given after the radiotherapy. The primary end point was 2-year progression-free survival (PFS) in patients receiving rdWBRT. ...All examined MRIs (n = 28) displayed a Fazekas score of 3, and no patient developed scores of 4 to 5; differences in …
Consolidation cytarabine was given after the radiotherapy. The primary end point was 2-year progression-free survival (PFS) in patien …
Cytarabine and neurologic toxicity.
Baker WJ, Royer GL Jr, Weiss RB. Baker WJ, et al. J Clin Oncol. 1991 Apr;9(4):679-93. doi: 10.1200/JCO.1991.9.4.679. J Clin Oncol. 1991. PMID: 1648599 Review.
In the past decade, neurotoxicity has been an increasingly recognized cytarabine effect. Intrathecal (IT) cytarabine may result in myelopathy that is incompletely reversible. ...
In the past decade, neurotoxicity has been an increasingly recognized cytarabine effect. Intrathecal (IT) cytarabine ma …
The toxicity of cytarabine.
Stentoft J. Stentoft J. Drug Saf. 1990 Jan-Feb;5(1):7-27. doi: 10.2165/00002018-199005010-00003. Drug Saf. 1990. PMID: 2178634 Review.
Conversely, continuous infusion may be less neurotoxic. The antileukaemic effect of continuous infusion high-dose cytarabine is less well established. The only significant toxicity of low-dose cytarabine is myelosuppression. Given the generally poor condition …
Conversely, continuous infusion may be less neurotoxic. The antileukaemic effect of continuous infusion high-dose cytarabine i …
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2022 Dec;9(12):e878-e885. doi: 10.1016/S2352-3026(22)00285-X. Epub 2022 Oct 22. Lancet Haematol. 2022. PMID: 36279879 Clinical Trial.
Patients received four cycles of intensive chemotherapy (hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] alternating with high-dose methotrexate and cytarabine), followed by four cycles of blinatumomab consolidation (up to 28 mu …
Patients received four cycles of intensive chemotherapy (hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexam …
Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function.
Zhuo M, Gorgun MF, Englander EW. Zhuo M, et al. Free Radic Biol Med. 2018 Jun;121:9-19. doi: 10.1016/j.freeradbiomed.2018.04.570. Epub 2018 Apr 23. Free Radic Biol Med. 2018. PMID: 29698743 Free PMC article.
Peripheral Nervous System (PNS) neurotoxicity caused by cancer drugs hinders attainment of chemotherapy goals. ...The objective of this work was to elucidate progression of events triggered by antimitotic drugs in postmitotic neurons. For proof of mechanism study, we chose …
Peripheral Nervous System (PNS) neurotoxicity caused by cancer drugs hinders attainment of chemotherapy goals. ...The objective of th …
Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.
Dotson JL, Jamil MO. Dotson JL, et al. Int J Hematol. 2018 Nov;108(5):554-557. doi: 10.1007/s12185-018-2485-4. Epub 2018 Jun 26. Int J Hematol. 2018. PMID: 29946854
Neurotoxicity from high-dose cytarabine, a pyrimidine metabolite used in treatment for acute myeloid leukemia, is a known but dose-limiting toxicity which has incidences in up to 14% in patients receiving high doses of the drug. ...There are no validated treatments …
Neurotoxicity from high-dose cytarabine, a pyrimidine metabolite used in treatment for acute myeloid leukemia, is a known but …
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. Omuro A, et al. Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7. Blood. 2015. PMID: 25568347 Free PMC article. Clinical Trial.
In conclusion, this treatment was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of neurotoxicity thus far. This trial was registered at www.clinicaltrials.gov as NCT00596154....
In conclusion, this treatment was associated with excellent disease control and survival, an acceptable toxicity profile, and no evidence of …
251 results